What happened with ROIV today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Roivant Sciences acquires or licenses drug candidates and develops them through Vants, each with its own management team. Its pipeline includes brepocitinib, under FDA review for dermatomyositis, and IMVT-1402, being developed for autoimmune diseases. It has no approved products and cannot sell these medicines before regulatory approval. Future drug sales depend on successful trials, approval and insurance coverage; Roivant relies on outside manufacturers for supply and owes licensors milestone payments and royalties.
Its current revenue comes mainly from Genevant, which helps pharmaceutical and biotechnology partners deliver nucleic-acid medicines into cells. Partners pay for access to its delivery technology and development work, with agreements seeking upfront payments, research reimbursements and further payments linked to development or commercial success. Genevant and Arbutus also reached a patent settlement with Moderna that grants Moderna a non-exclusive delivery-technology license for infectious diseases. The settlement provides a fixed payment and a further payment dependent on an appeal’s outcome, rather than recurring drug sales.
Roivant has also funded its business by selling subsidiaries, including Telavant to Roche and Dermavant to Organon. The Dermavant sale retains potential milestone and royalty payments tied to VTAMA sales, so that cash depends on Organon’s commercial performance.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Roivant’s value depends on brepocitinib and mosliciguat development and its HanAll-licensed IMVT-1402 program, not just Genevant’s patent proceeds.
Immunovant, Inc. is Roivant’s majority-owned drug-development subsidiary, so its IMVT-1402 clinical progress directly affects Roivant’s pipeline value. It has earned no revenue since inception; product sales depend on completing development and winning approval for IMVT-1402 or another candidate.
Arbutus Biopharma Corporation supplies patents for technology that delivers genetic material into cells to Roivant’s Genevant, which owes it royalties, and shares Genevant’s Moderna settlement proceeds and vaccine-patent litigation exposure. Watch the still-unresolved Comirnaty damages claim: the Moderna settlement does not establish how that case will end.
Moderna pays Roivant’s Genevant and Arbutus under a settlement that gives the vaccine seller a license to technology for delivering genetic material into cells, called LNP, for infectious-disease applications. Beyond the $950 million payable by July 2026, another $1.3 billion depends on a ruling in Moderna’s §1498 appeal favorable to Genevant and Arbutus.
Pfizer sells Comirnaty and faces patent claims from Roivant’s Genevant and Arbutus that could bring substantial proceeds to Roivant, although liability remains disputed. Watch the Comirnaty litigation rather than treating Moderna’s settlement as a guide: Pfizer’s case remains unresolved.
BioNTech co-develops and commercializes Comirnaty and is a defendant in the unresolved patent damages action brought by Roivant’s Genevant and Arbutus. Its exposure matters to Roivant’s potential patent proceeds; watch rulings on Comirnaty’s manufacture and sale, which the Moderna settlement did not resolve.
Dianthus Therapeutics, Inc. is developing claseprubart for CIDP, competing for the same patients targeted by Roivant’s IMVT-1402 program. It has no approved products or commercial product sales, so claseprubart’s CIDP clinical progress—not current sales—is the competitive signal to watch.
Viridian Therapeutics, Inc.’s thyroid eye disease treatments could compete with the anti-FcRn therapies pursued by Roivant’s Immunovant. Kissei pays Viridian for Japanese rights to veligrotug and elegrobart and handles local development and commercialization, making their Japanese approval progress a concrete development to watch.
Pfizer Inc. earningsPFE
Pfizer’s report can show Comirnaty sales and any disclosed litigation update, giving context for the unresolved patent claims brought by Roivant’s Genevant and Arbutus.
Keep Pfizer’s reported Comirnaty sales separate from any patent-case update. Sustained sales would show the product remains commercially relevant, but would not prove infringement; weaker sales would mean a smaller current commercial footprint, not that the case is resolved. Any disclosed case development would clarify where the claim stands. The report can show the product’s commercial context, not determine whether Roivant’s affiliates will prevail.
Dianthus Therapeutics, Inc. earningsDNTH
Dianthus Therapeutics’ report will show how its CIDP drug candidate claseprubart is progressing against IMVT-1402, which Roivant subsidiary Immunovant is developing for the same patients.
Watch claseprubart’s clinical progress, not sales: Dianthus has no approved products. Progress would make competition for the same CIDP patients more concrete and give those patients another potential treatment option; setbacks could ease that pressure but would not prove IMVT-1402 works. The question is whether Dianthus is becoming a more credible competitor in this indication.
Moderna, Inc. earningsMRNA
Moderna’s report may update the §1498 appeal, which affects whether Genevant and Arbutus receive the settlement’s contingent $1.3 billion payment.
Look for any update Moderna gives on its §1498 appeal. A ruling favorable to Genevant and Arbutus under the settlement would make the contingent $1.3 billion payment due; an unfavorable ruling or an unresolved appeal would leave that additional payment uncertain. The takeaway is whether this potential settlement proceeds are closer to being realized; the report itself cannot replace a court ruling.
Roivant Sciences Ltd. earningsThis company
Roivant earns most of its revenue from Genevant’s license agreements, and this report will show whether that income is contributing to drug development beyond the litigation settlement gain.
Read license-agreement revenue alongside cash used in operations, and keep both separate from the litigation settlement gain. Steadier license revenue with contained cash use would show the business is helping fund development more consistently; low license revenue with heavy cash use would show Roivant still depends on its reserves and one-off gains to carry those costs. The question is whether its revenue engine is keeping pace with pipeline spending.
Immunovant, Inc. earningsIMVT
Immunovant is Roivant’s drug-development subsidiary, and its report will show how IMVT-1402 is progressing, a key part of Roivant’s pipeline.
Look for updates on IMVT-1402’s clinical development and how Immunovant is directing its research spending. Clear progress would show that this important Roivant program is moving forward; delays or setbacks would make its path to the next development stage less certain. The takeaway is whether this pipeline program is advancing, not whether approval is assured.
